당뇨병성 말초혈관병증에서 항혈소판제의 효과: 발목상완지수 및 맥파전달속도를 통한 비교
Effect of Antiplatelets in Diabetic Peripheral Vasculopathy: Comparison by Ankle-Brachial Index and Peak Wave Velocity
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study is to confirm the effect of antiplatelet drugs in diabetic peripheral vasculopathy in diabetic foot patients. Materials and Methods: We designed a retrospective study in diabetic foot patients with diabetic peripheral vasculopathy. From October 2007 to December 2013, 278 cases in 139 patients who took antiplatelet drugs over at least a six-month period were included in this study. We categorized these patients according to the type of drug used. The efficacy of antiplatelet drugs was evaluated using anklebrachial index (ABI) and pulse wave velocity (PWV). Results: Only the aspirin group showed a statistically significant increase of ABI after antiplatelet therapy (1.10±0.12 to 1.12±0.11). In addition, only the cilostazol group showed a statistically significant decrease of PWV after antiplatelet therapy (1,701.20±396.56 to 1,627.42±324.98). Conclusion: Aspirin and cilostazol may be used in treatment of diabetic peripheral vasculopathy, whereas dual antiplatelet therapy with aspirin and clopidogrel has no specific benefits in diabetic peripheral vasculopathy.
Abstract
Purpose: The purpose of this study is to confirm the effect of antiplatelet drugs in diabetic peripheral vasculopathy in diabetic foot patients. Materials and Methods: We designed a retrospective study in diabetic foot patients with diabetic peripheral vasculopathy. From October 2007 to December 2013, 278 cases in 139 patients who took antiplatelet drugs over at least a six-month period were included in this study. We categorized these patients according to the type of drug used. The efficacy of antiplatelet drugs was evaluated using anklebrachial index (ABI) and pulse wave velocity (PWV). Results: Only the aspirin group showed a statistically significant increase of ABI after antiplatelet therapy (1.10±0.12 to 1.12±0.11). In addition, only the cilostazol group showed a statistically significant decrease of PWV after antiplatelet therapy (1,701.20±396.56 to 1,627.42±324.98). Conclusion: Aspirin and cilostazol may be used in treatment of diabetic peripheral vasculopathy, whereas dual antiplatelet therapy with aspirin and clopidogrel has no specific benefits in diabetic peripheral vasculopathy.
참고문헌 (28)
- IDF diabetes atlas, "International Diabetes Federation", International Diabetes Federation, ~ (2013)
- DiMinno G, "Trial of repeated low-dose aspirin in diabetic angiopathy", Blood, 68, pp.886~891 (1986)
- Colwell JA, "Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates", Diabetes Care, 9, pp.140~148 (1986)
- Bridges JM, "An effect of Dglucose on platelet stickiness", Lancet, 1, pp.75~77 (1965)
- Colwell JA, "The platelet in diabetes : focus on prevention of ischemic events", Diabetes Care, 26, pp.2181~2188 (2003)
- Angiolillo DJ, "Antiplatelet therapy in diabetes : efficacy and limitations of current treatment strategies and future directions", Diabetes Care, 32, pp.531~540 (2009)
- Ogawa H, "Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial", JAMA, 300, pp.2134~2141 (2008)
- Belch J, "The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease", BMJ, 337, pp.a1840~ (2008)
- Begelman SM, "Noninvasive diagnostic strategies for peripheral arterial disease", Cleve Clin J Med, 73(4), pp.S22~S29 (2006)
- Mackenzie IS, "Assessment of arterial stiffness in clinical practice", QJM, 95, pp.67~74 (2002)
- Brooks B, "TBI or not TBI : that is the question", Is it better to measure toe pressure than ankle pressure in diabetic patients? Diabet Med, 18, pp.528~532 (2001)
- Jeffcoate WJ, "Diabetic foot ulcers", Lancet, 361, pp.1545~1551 (2003)
- Reiber GE, "Diabetes in America", pp.409~428 (1995), NIH publications
- Singh N, "Preventing foot ulcers in patients with diabetes", JAMA, 293, pp.217~228 (2005)
- Lipsky BA, "Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection", Diabetes Care, 34, pp.1695~1700 (2011)
- Anderson JL, "Management of patients with peripheral artery disease(compilation of 2005 and 2011 ACCF", AHA guideline recommendations) : a report of the American College of Cardiology Foundation, Circulation, pp.2013, 127[DOI]
- CAPRIE Steering Committee, "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE)", Lancet, 348, pp.1329~1339 (1996)
- Bhatt DL, "Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus", Am J Cardiol, 90, pp.625~628 (2002)
- Ohashi S, "Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion", Arzneimittelforschung, 35, pp.1203~1208 (1985)
- Uchikawa T, "Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus", Arzneimittelforschung, 42, pp.322~324 (1992)
- Katz MF, "Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor", J Leukoc Biol, 55, pp.567~573 (1994)
- Yamakawa J, "Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans", J Int Med Res, 32, pp.166~169 (2004)
- Norgren L, "Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study", Vasc Med, 11, pp.75~83 (2006)
- Ahn JC, "Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel", Korean J Intern Med, 19, pp.230~236 (2004)
- Lee BK, "Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation", Am J Cardiol, 100, pp.610~614 (2007)
- Cassar K, "Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty", Br J Surg, 92, pp.159~165 (2005)
- Bhatt DL, "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events", N Engl J Med, 354, pp.1706~1717 (2006)
- Berger JS, "Bleeding, mortality, and antiplatelet therapy : results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance(CHARISMA)trial", Am Heart J, 162, pp.98~105 (2011)